Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3108
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines.

    To find out more about Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
AC Immune
Actinium Pharmaceuticals
Adaptimmune
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alfacell
Allos Therapeutics
AlphaVax
Altor BioScience
Ambit Biosciences
Amgen
Antisoma
Anza Therapeutics
Apricus Biosciences
Arca biopharma
Argos Therapeutics
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Bio-Path Holdings
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biolex
BioNTech
BioSante
Biostar
Bioton
BioVex
Boehringer Ingelheim
Borean Pharma
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Center of Molecular Immunology
Cephalon
CG Therapeutics
Choongwae
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Curacyte
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
Favrille
Forma Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GenPat77
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GlycoMimetics
Gradalis
Hanmi
Hayashibara
Heat Biologics
Heber Biotec
HemaQuest
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IGF Oncology
IkerChem
ImClone Systems
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kanisa
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
MedImmune
Memgen
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
Noxxon
Nycomed Pharma
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
Protherics
Radient Pharmaceuticals
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Reliance Life Sciences
responsif
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Southern Research Institute
Spirogen
Stemline Therapeutics
SuperGen
SuppreMol
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
TeGenero
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Therion Biologics
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
XBiotech
Xencor
Yakult Honsha
Yamasa Corporation
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
ADXS11-001
AE-37
AGS-003
alemtuzumab
amonafide malate
amrubicin hydrochloride
amsacrine
ANZ-207
astuprotimut-r
Auto TAG vaccine
AVX-701
barasertib
belagenpumatucel-L
belinostat
bexarotene
bisantrene
bortezomib
bosutinib
BP-GMAX-CD1
brentuximab vedotin
BV-NSCLC-001
CB-10-01
CDX-1307
CG-201
cladribine
clofarabine
CreaVax-PC
CSF-GM
CV-9103
CV-9201
CVac
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
DCVax-prostate
decitabine
denileukin diftitox
E-75
elacytarabine
elliptinium acetate
emepepimut-S
enocitabine
enzastaurin hydrochloride
epirubicin
everolimus
galiximab
gemtuzumab ozogamicin
GI-4000
GSK-2130579A
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
HS-110
ibritumomab tiuxetan
ICT-107
idarubicin
imatinib mesilate
imMucin
IMO-2055
inotuzumab ozogamicin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukin-12
irinotecan hydrochloride
ISA-P53-01
JX-594
lestaurtinib
leukemia vaccine
lumiliximab
MDX-1379
MGN-1601
midostaurin
mitoxantrone
MVA-BN Her-2 vaccine
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
panobinostat
peginterferon alfa-2b
pentostatin
pixantrone
poly-ICLC
polyclonal antibody stimulator
pralatrexate
PROSTVAC
PSMA ADC
razoxane
Reditux
Reximmune-C
rhIFN-alpha
rindopepimut
rintatolimod
rituximab
romidepsin
S-488410
SCIB-1
sipuleucel-T
sobuzoxane
Survivac
tamibarotene
temsirolimus
teniposide
TG-4010
thymalfasin
tipapkinogene sovacivec
tipifarnib
TroVax
velimogene aliplasmid
verpasep caltespen
vitespen
vosaroxin
VX-001
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines.
    To find out more about Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Pancreatic Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Lung Cancer, Pancreatic Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Lymphoma, Melanoma and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Apoptosis. Learn More